ãå®å šã§å¹æçãã¯ç§åŠçãªçµè«ã§ã¯ãªããããŒã±ãã£ã³ã°ã®ã¹ããŒã¬ã³ã ã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ãå®å
šã§å¹æçããšããã®ã¯ç§åŠççµè«ã§ã¯ãªãããŒã±ãã£ã³ã°çšã®ã¹ããŒã¬ã³ã§ããã補é å
èªèº«ã®æ²»éšããŒã¿ã¯ãéç¯€ãªæå®³äºè±¡ã®éå°çºçã瀺ããŠããŸãããèŠå¶åœå±èªèº«ã®ã¢ã¯ãã£ãç£èŠã§ã¯ã7人ã«1人ãå»åŠçã«æ·±å»ãªåå¿ãå ±åããŠããããšãåãããŸããããããŸã§ã§æå€§èŠæš¡ã®å®å
šæ§ç ç©¶ã¯ãç°è«ãå±ããå»åž«ãã¡ãåé¡æèµ·ããäž»èŠãªã·ã°ãã«ããã¹ãŠè£ã¥ããŸãããå
ç«æ©åºã®ããŒã¿ã¯ãç¹°ãè¿ãæäžãé广ã ã£ãå¯èœæ§ã瀺ããŠããŸãã3補åã®ãã¡2ã€ã¯æ€åãããŠããŸãã
å»çå°éè·èªèº«ã®ã¯ã¯ãã³ãžã®ä¿¡é Œãæºããã2024/25幎ã®å»çåŸäºè
ã«ãããæ°åã³ããã¯ã¯ãã³æ¥çš®çã¯12ïŒ
æªæºã«ãŸã§äœäžããŸãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®æ¥çš®çãã2022幎ã®71ïŒ
ãã2025幎ã«ã¯45ïŒ
ãžãšäžãããŸããã
ãããŠãäºå®äžã¯ã¯ãã³æ¥çš®ã匷å¶ããã¢ã€ã«ã©ã³ãæ¿åºã¯ãäžçäžã§å€§èŠæš¡ã«èšé²ãããŠãããããªã被害ã«ã€ããŠããç ç©¶ã»ã¬ãã¥ãŒã»èª¿æ»ãäžã€ãšããŠå®æœããŠããŸããããšããŒã«ã»ãããã³ã¯èšããŠããŸãã
ãµã€ãšã³ã¹ãä¿¡ãã ããŒã8ïŒåœŒããèªããªãããŒã¿
ããŒã«ã»ãããã³èã2026幎5æ7æ¥
ããŒã¿
誰ããç¥ã£ãŠããŸããä»ã§ã¯èª°ããããã§ãã
æ°åã³ããã¯ã¯ãã³ãæ¥çš®ããåã¯ãŸã£ããå¥åº·ã ã£ãã®ã«ããã®åŸãã£ãšèª¿åãæªã誰ããçç±ããªãçªç¶åæžããã人ãäžæ©ã§è³é³Žãã«ãªã£ãåç¶ãæçµãå€ãã£ã効ãèšããããšããã«ãã¹ãŠãã£ãŠããã®ã«äœåºŠãæ°åã³ããã«ããã£ãŠããŸã芪ãå¥åº·ã ã£ãè¥è ãçªç¶äº¡ããªãã誰ã«ãçç±ã説æã§ããªãã
ãã®5幎éãããªãã¯ãããã話ãç®ã«ãããŸãã¯èããããŠããŸãããå¶ç¶ãäžå®ããã³ã°ã³ããããäžéãç§åŠã¯æ±ºçæžã¿ã§ãã¯ã¯ãã³ã¯å®å šã§æå¹ããããŠããã«çåãåããè ã¯èª€æ å ±ãæµããŠããããšèšãããŠããŸãããçŸå®ã«åãåããªãããšã«ã¯éœåã®ããããããç¡ç¥ã«ã¯è³çŠããããŸãã
ãã®å š8åã·ãªãŒãºã®æçµåã§ã¯ãããªãã®æ¿åºãå»çæ©é¢ããããŠã¡ãã£ã¢ãåãäžããŠããªããçºè¡šæžã¿ã§æ»èªãçµãæ©é¢ã®ç§åŠçç ç©¶ãæç€ºããŸããããã¯é°è¬è«çãªäž»åŒµãç¡åèªã®åšçžçç ç©¶ã§ã¯ãããŸãããäžçã§æãæš©åšããå»åŠã»ç§åŠèªãããªãã¡ Science ImmunologyãVaccineãDrug SafetyãNature Scientific ReportsãOpen Forum Infectious DiseasesãJournal of Infection ã«æ²èŒãããŠããŸããèè ã¯ãã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ãã°ããŒãã«ã»ã¯ã¯ãã³ã»ããŒã¿ã»ãããã¯ãŒã¯ãè±åœå»è¬åã»å»ç補åèŠå¶åºïŒMHRAïŒãã¹ã¿ã³ãã©ãŒã倧åŠãUCLAããããã³å€§åŠããã³ããŒã¯ã®åœç«è¡æž ç ç©¶æïŒStatens Serum InstitutïŒã®ç ç©¶è ãã¡ã§ããæ»èªæžã¿ã§ããªãŒãã³ã¢ã¯ã»ã¹ã§ãå ¬çã«å ¥æå¯èœã§ãã
ã¢ã€ã«ã©ã³ãã®ã¡ãã£ã¢ãå ¬çæ©é¢ã¯äžã€ãšããŠããããåŒçšããŠããŸãããHPRA ã¯ãããã«èšåããŠããŸãããHSE ã¯ããã«åºã¥ãè¡åãåã£ãŠããŸãããCovid è©äŸ¡ã§ã¯ãã¯ã¯ãã³ã«ããæå®³äºè±¡ãæ€èšå¯Ÿè±¡ããå€ãããŸããããããŠãã¢ã€ã«ã©ã³ãã®äž»æµã¡ãã£ã¢ã®èšè ã¯ããã®é©ãã¹ãçºèŠã«ã€ããŠãååãªæ·±ãã§å ±ããŠããŸããã
å¢å°ã®æ æ¯ã§ããç§åŠãä¿¡ããããšå»ãŸãã幎å·ã1984â2021ãšèšãããå¢ç³ã

以äžã«è¿°ã¹ãäžã§æã糟匟ãã¹ãç¹ã¯ããããã®ã¯ã¯ãã³ãå°å ¥ãããåã«ãæ¬ç©ã®ç§åŠè ãã¡ãèµ·ããåŸãäºæ ãèŠåããŠããããšã§ããæ¥çš®ãé²ãäžã§ããä»ã®äººã ãæžå¿µãäžç©ãªåŸåã«æãç«ãŠãŠããŸããã圌ãã¯çµç¹çã«é»ããããŸããã
1:7人ã«1人
2025幎9æãè±åœã®å»è¬åèŠå¶åœå±ã§ããMHRAã¯ãã¹ããªã³ã¬ãŒã®ãã¡ãŒãã³ããžã©ã³ã¹èªDrug Safetyã«ã€ãšããŒã«ãŒãã»ã¯ã¯ãã³ã»ã¢ãã¿ãŒã®çµæãçºè¡šããŸãããããã¯ååçå ±åïŒäººã ãèªçºçã«èŠæ ãæåºãããã®ïŒã§ã¯ãããŸãããèœåçãµãŒãã€ã©ã³ã¹ã§ãããã€ãŸããMHRAãã¯ã¯ãã³æ¥çš®è ã«ç»é²ãåŒã³ããããããããæ±ºããééã§ãã®åŸã®çµéãå°ããŠè¿œè·¡ããã®ã§ãã
ã¯ã¯ãã³æ¥çš®ãåããèœåçã«ã¢ãã¿ãªã³ã°ããã30,281人ã®ãã¡ã52.1%ãå°ãªããšã1ä»¶ã®æå®³äºè±¡ãå ±åããŸããããããŠ13.7%âããã7人ã«1人âãå»åŠçã«é節ãšåé¡ãããåºæ¥äºãå ±åããŸããã
ãã®ç ç©¶ã§ã¯ãåå è ã®7人ã«1äººãæ·±å»ãªå»çäžã®åºæ¥äºãçµéšããŸãããæ¥çš®åŸã®èœåçã¢ãã¿ãªã³ã°ã«ç»é²ãã人ã®ãã¡3人ãããã®åŸæ»äº¡ãšèšé²ãããŸããã芳å¯å¯Ÿè±¡ã®303人ã«1人ãåæžãå ±åãç¥çµåŠçãªæèŠå€åãå ±åãã人ã¯269人â芳å¯å¯Ÿè±¡ã®ããã100人ã«1人ã§ãããªã³ãç³»ã®åé¡ãå ±åãã人ã¯130人ã«1人ãèŠèŠé害ã倱æ1äŸãå«ãçŒé害ã¯145人ã«1人ã§ãããçèæ³šå°ã§ç®ã®çã¿ãæ³å®ããäººã¯æ®éããŸããã
ãã®ç ç©¶ã®çµè«èªäœã¯ãããŒã¿ãã奜ãŸããå®å šæ§ãããã¡ã€ã«ããæ¯æãããšèšè¿°ããŠããŸãããèè ãã¯ãã»ãšãã©ã®åå¿ããäºæãããæ¥æ§åå¿ãâããªãã¡èšåºè©Šéšã§ãã§ã«ç¹å®ãããŠããå 容ãšäžèŽããŠããâãšææããŸããããããã人ã ã¯æ¥æ§åå¿ã®å¯èœæ§ã«ã€ããŠèŠåãåããŠããã®ã§ãããããæ¥çš®åã«å»åž«ãè °ãæ®ããŠãã¯ã¯ãã³ãæã£ããäœãèµ·ããåŸãã説æããŠãããèšæ¶ã¯ãããŸããããããšããã£ãšåçŽã ã£ãã§ãããããè¢ããŸããããã¯ãªã2é±éåŸã«è¿œå æ¥çš®ã§ãŸãäŒããŸãããããšã
æåŸ ãšäžèŽããŠãããããšãã£ãŠã被害ã®èŠæš¡ãå°ãããªãããã§ã¯ãããŸããã500äžäººã«æ¥çš®ããŠ7人ã«1人ãå»åŠçã«é節ãªåºæ¥äºãçµéšããã°ã70äžäººä»¥äžã«åœãããŸãããã®ç ç©¶ã¯è±åœã®èŠå¶åœå±ã宿œããMHRAè·å¡ã®ååã§çºè¡šããããªã³ã©ã€ã³ã§èªç±ã«é²èЧã§ããŸããã¢ã€ã«ã©ã³ãã®ã¡ãã£ã¢ã§ã¯äžåå ±ããããŠããŸããã
2:補é å èªèº«ã®æ²»éšããŒã¿
ã¯ã¯ãã³ãæ¿èªãããåããã¡ã€ã¶ãŒãšã¢ãã«ãã¯ãç·æ¥äœ¿çšèš±å¯ïŒEUAïŒã®æ ¹æ ãšãªã£ã第IIIçžèšåºè©Šéšã宿œããŸããã2022幎ãUCLAãã¹ã¿ã³ãã©ãŒãããã³ã倧åŠãã¡ãªãŒã©ã³ã倧åŠã®ç¬ç«ç ç©¶ããŒã ããåãæ²»éšã®éç¯€ãªæå®³äºè±¡ããŒã¿ãåè§£æããŸããã圌ãã®ç ç©¶ã¯ãäºé²æ¥çš®åéã®äž»èŠèªã§ããVaccineã«æ²èŒãããPubMedã§ãé²èЧã§ããŸãã
ç¬ç«ç ç©¶è ãã¯ããã©ã€ãã³ã»ã³ã©ãã¬ãŒã·ã§ã³ã®ãç¹ã«æ³šç®ãã¹ãæå®³äºè±¡ãã®äžèЧâWHOãã¯ã¯ãã³å®å šæ§ç£èŠã®æšæºãšããŠæ¿èªãããã®âãçšããŸããããã®çµæããã¡ã€ã¶ãŒãšã¢ãã«ãã®äž¡ã¯ã¯ãã³ã§ãç¹ã«æ³šç®ãã¹ãéç¯€ãªæå®³äºè±¡ã®éå°ãªã¹ã¯ã確èªãããŸããããã©ã»ã矀ã«å¯ŸããŠããã¡ã€ã¶ãŒã¯1äžäººããã10.1ä»¶ãã¢ãã«ãã¯1äžäººããã15.1ä»¶ã§ãã
å¹³ããèšãã°ã補é å èªèº«ã®æ²»éšã«ãããŠãæ¥çš®çŸ€ã¯éæ¥çš®çŸ€ããéç¯€ãªæå®³äºè±¡ãå€ããæ¯çã«ããŠ10察1ã15察1ã®æ°Žæºã§ãããã¯ã¯ãã³ã«ããé節ãªå®³ã®éå°ãªã¹ã¯ã¯ãã¯ã¯ãã³ãããããæ°åã³ããå ¥é¢æžå°ãšåçšåºŠã®ç¯å²ã«ãããŸãããèè ãã¯ãæ£åŒãªå®³çåæãç¹ã«é節ãªCOVID-19転垰ã®ãªã¹ã¯ã«å¿ããå±€å¥ååæããæ±ããŸãããå±€å¥åãšã¯å¹Žéœ¢ãå¥åº·ç¶æ ã§åããããšã§ãå¥åº·ãª25æ³ãã¯ã¯ãã³ãšãŠã€ã«ã¹ã®ã©ã¡ããããã倧ããªãªã¹ã¯ãåããã®ããç¥ãããã§ãã
ãã®åæã¯å®æœãããŸããã§ããããã¡ã€ã¶ãŒãã¢ãã«ãããEMAãHPRAããã¢ã€ã«ã©ã³ãã®ãããªãä¿å¥æ©é¢ãè¡ã£ãŠããŸããã
3:9,900äžäºº
2024幎2æãWHOãšé£æºããåœéå ±åäœã§ããGlobal Vaccine Data Networkããéå»æå€§èŠæš¡ã®ã¯ã¯ãã³å®å šæ§ç ç©¶ãçºè¡šããŸããã8ãåœ10æ ç¹ã«ãããã9,900äžäººã®æ¥çš®è ã察象ãšããVaccineèªã«æ²èŒãããŸãããã¹ã³ããã©ã³ãããã¥ãŒãžãŒã©ã³ãããã©ã³ã¹ããªãŒã¹ãã©ãªã¢ããã£ã³ã©ã³ãããã³ããŒã¯ãã«ããã®æ£è ãå«ãŸããŸãã
ãã®ç ç©¶ã¯ã3倧ã¯ã¯ãã³ïŒãã¡ã€ã¶ãŒãã¢ãã«ããã¢ã¹ãã©ãŒãã«ïŒã®ãã¹ãŠã§ãå¿ççãšå¿èçâå¿çãšå¿å€èã®ççâã«é¢ããçµ±èšåŠçã«ææãªå®å šæ§ã·ã°ãã«ã確èªããŸãããã¢ã¹ãã©ãŒãã«åŸã§ã¯ã®ã©ã³ã»ãã¬ãŒçå矀âå ç«ç³»ãç¥çµãæ»æããçåäœäžãæã«éº»çºãåŒãèµ·ããâã確èªãã¢ã¹ãã©ãŒãã«åŸã§ã¯è³éèæŽè¡æ çâè³å ã®è¡æ âã確èªããããŠãæšªææ§èé«çïŒèé«ã®ççïŒãæ¥æ§æ£åšæ§è³èé«çïŒè³ãšèé«ã®ççïŒã«ã€ããŠãæ°ããªå¯èœæ§ã®ããã·ã°ãã«ãç¹å®ããèè ãã¯ããããªã調æ»ãå¿ èŠããšè¿°ã¹ãŸããã
ãããŸã§ç°è«ãå±ããå»åž«ãã¡ãåãäžããŠæ€é²ãããäž»èŠãªå®å šæ§ã·ã°ãã«ã¯ãå²äžæå€§ã®ç ç©¶ã§ãããã確èªãããŸãããèè ããæšå¥šããããããªã調æ»ãã¯HSEã«ãã£ãŠå®æœãããŠããŸããã
ãã®ç ç©¶ã¯ç¹å®ã®13çŸæ£ã«ããç®ãåããŠããŸãããMHRAã129人ã«1人ã§èŠåºãããªã³ãç¯çããçŒé害ãæçµç°åžžãè³é³ŽããæèŠç°åžžïŒãã¬ã¹ããžã¢ïŒããã®ä»MHRAã®OSM Resource 8ãèšé²ããæ°åã®åå¿ã¯å¯Ÿè±¡å€ã§ããã
4:10代ã®çŽ30%ã«å¿è¡ç®¡ãžã®åœ±é¿
2022幎ãã¿ã€ã»ãã³ã³ã¯ã®ãããã³å€§åŠã®ç ç©¶è ãã¡ã¯ã西åŽã®èŠå¶åœå±ã誰ããããªãã£ãããšã宿œããŸããã13ã18æ³ã®ã¿ã€äººéå°å¹Ž301人ã«ã€ããŠã2åç®ã®ãã¡ã€ã¶ãŒæ¥çš®åã«ECGïŒå¿é»å³ïŒãå¿ãšã³ãŒãå¿çãã€ãªããŒã«ãŒã®è¡æ¶²æ€æ»ã§ããŒã¹ã©ã€ã³ãåããæ¥çš®åŸ3æ¥ã7æ¥ã14æ¥ã«ã¢ãã¿ãªã³ã°ããã®ã§ããTropical Medicine and Infectious Diseaseã«æ²èŒããããã¡ãã§é²èЧã§ããŸãã
åå è ã®29.24%ã«å¿è¡ç®¡ã®åœ±é¿ãèŠãããŸãããã¯ã¯ãã³æ¥çš®ãåãã10代ã®çŽ3人ã«1人ãå¿èã®äžèª¿ãçµéšããã®ã§ããæãäžè¬çã ã£ãã®ã¯ãå®éæå¿ææ°100å/åè¶ ïŒ7.64%ïŒãæ¯åãïŒ6.64%ïŒãåæžïŒ4.32%ïŒãèžçïŒ4.32%ïŒãé«è¡å§ïŒ3.99%ïŒã7人ïŒ2.33%ïŒã¯å¿çãã€ãªããŒã«ãŒã®äžæã瀺ããè¡æ¶²æ€æ»ãå¿çæå·ã瀺åããŸããã
ä»ã®ç ç©¶ããæ°å€ãé«ãã£ãçç±ã¯ãã¿ã€ã®ç ç©¶è ãæ¥çš®åã®ããŒã¹ã©ã€ã³ã枬å®ããããã§ããããŒã¹ã©ã€ã³ããªããã°ãæãããªçç¶ãåºãŠããªãæœåšçãªæå·ã¯æ€åºã§ããŸããã西åŽã®å€ãã®ç£èŠã¯ãçç¶ãåºãŠç é¢ãå蚺ãã人ã ã«äŸæ ããŠããŸãããã¿ã€ã®ç ç©¶ã¯ã10代ãäžèª¿ãæããŠãããã©ããã«ãããããæå·ãæ¢ããŸããããã®çµæãã»ãŒ3人ã«1人ã§èŠã€ãã£ãã®ã§ãã
ç ç©¶ã®çµè«ã§ã¯ãããã®é幎ã³ããŒãã§èгå¯ãããå¿è¡ç®¡ã®æå®³äºè±¡ã¯ããããã軜床ã§äžéæ§ã§ãã£ãããšèšãããŸãããé·æçã«ãããã§ããããšãé¡ããŸããããããªãçš®é¡ã®å¿è¡ç®¡ã®åé¡ããææèŽæ»çïŒIFRïŒãçŽ0.003%ã®ææ¥æã«ãšã£ãŠã¯é«ããã代åã«æããŸããæªæå¹Žã«æ¥çš®ãããåŠãã®åãã¯ãããèŠçŽã§ããŸãã3äž3,333人ã«1äººã®æ»äº¡ãé¿ããããã«ã3人ã«1人ã®å¿èã®åé¡ãåãå ¥ããå¿ èŠããããšèšãããããã©ãããŸããã
UCSFã®Vinay Prasadææã¯ããã¹ãŠã®åœã§åãããã¹ãã ã£ãçåãæç€ºããŸãããããªãç±³åœã§ã¯ãã®ãããªç ç©¶ãè¡ãããŠããªãã®ãïŒã ã¢ã€ã«ã©ã³ãã§ãè¡ãããŸããã§ãããã¢ã€ã«ã©ã³ãã®ã©ã®10代ã«ã€ããŠããæ¥çš®ååŸã®ããŒã¹ã©ã€ã³å¿æ©èœã¢ãã¿ãªã³ã°ã¯å®æœãããŠããŸããããããã£ãŠãæå·ã®çšåºŠã¯æ£ç¢ºã«ã¯ææ¡ã§ããã10代ãè¥å¹Žæäººã®å¿è¡ç®¡åœ±é¿ãäºåã«å¯ç¥ããããšã¯ãå»çãµãŒãã¹ã«ãšã£ãŠå€§ããªåŸæ¹æ¥åäžã®è² æ ã«ãªãã§ãããã
2025幎9æã®è±åœã§ã¯ãOpenSAFELYã®ç ç©¶ããå¿ççãšå¿èçãæ¥çš®çŸ€ã«ã®ã¿èŠãããããšã瀺ããŸãããéæ¥çš®çŸ€ã§ã¯å¿èã®åé¡ã¯ãŒãã§ããããŸãã5ã15æ³ã®åã©ã126äžäººã®ã³ããŒãã§ã¯ã䞡矀ãšãæ°åã³ããã«ããæ»äº¡ã¯ãŒãã§ããã
5:å ç«ç³»ããŠã€ã«ã¹ãç¡èŠããããšãåŠç¿ããŠãã
ãã€ãã®ããªãŒããªãã»ã¢ã¬ã¯ãµã³ããŒå€§åŠã®ç ç©¶è ãã¡ã¯ã2023幎1æã«äžçã§æãæš©åšããå ç«åŠèªã®äžã€ã§ããScience Immunologyã«ããªãå€ãã®æ¥çš®è ãäœåºŠãCOVIDã«ãããã®ãã説æãåŸãç ç©¶ãçºè¡šããŸããã
å ç«ç³»ã¯ç°ãªãã¿ã€ãã®æäœãç£çããŸãããŠã€ã«ã¹ãšæŠãäžã§æãŸããã®ã¯IgG1ãšIgG3âææçŽ°èãæ»æã»ç Žå£ããæ»æçã§ççæ§ã®æäœâã§ããIgG4ã¯ç°ãªããŸããããã¯å ç«å¯å®¹ã«é¢é£ããæäœã§ãäœãäœããšéãã®ã§ã¯ãªãå ±åããããšãåŠã¶éã«ç£çãããŸããIgG4ã¯ãç¹°ãè¿ãééãããã¡ã«è åšã§ã¯ãªããšå€æãããšãã«äœãããŸããäŸãã°é€èå®¶ã¯ãäœå¹Žãåºããç¶ãããã¡ã«IgG4ãå¢ããæ¯ã«åå¿ããèããããã«ãªããŸããããã°éäŒã®æäœã§ãã
èŠããã«ãå ç«ç³»ã¯ææãšéãããã«ç°ãªãã¿ã€ãã®æäœã䜿ãåããŸããã¯ã©ã¹ã¹ã€ããã³ã°ãšåŒã°ããããã»ã¹ãéããŠãã©ã®ã¿ã€ãã䜿ãããåãæ¿ããããšãã§ããå埩çãªmRNAæ¥çš®ã«ãã£ãŠãæ»æçã§ãŠã€ã«ã¹ã殺ãæäœãããå ç«ç³»ã«åæ¢ãä¿ãååçãªæäœãžãšç£çãåãæ¿ãã£ãã®ã§ãã
ãã€ãã®ç ç©¶è ã¯ãmRNAã¯ã¯ãã³2åç®æ¥çš®åŸãã¹ãã€ã¯ç¹ç°çæäœã«å ããIgG4ã®å²åã¯ããã0.04%ã ã£ãã®ãã3åç®æ¥çš®åŸã«ã¯19.27%ã«äžæããããšãèŠåºããŸããããã®ã·ããã¯ãŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ïŒã¢ã¹ãã©ãŒãã«ãªã©ïŒãèªç¶ææåŸã«ã¯èŠããããã¢ãã«ããšãã¡ã€ã¶ãŒã®ã¯ã¯ãã³ã«ã®ã¿åœãŠã¯ãŸããŸãã
mRNAã®ã¿ã®çŸ€ã¯ãã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒäœµçšçŸ€ã«æ¯ã¹ãŠãIgG4ã¬ãã«ã13ã20åé«ããªããŸãããã¯ã©ã¹ã¹ã€ããã¯mRNAãã©ãããã©ãŒã ç¹æã®ãã®ã§ããã¢ã¹ãã©ãŒãã«ã®ã¯ã¯ãã³ãèªç¶ææã§ã¯åãåå¿ã¯èµ·ããŸããã§ãããç¹°ãè¿ãã®mRNAæ¥çš®ã ããåŒãèµ·ãããã®ã§ãã
å¹³ããèšãã°ãç¹°ãè¿ãã®mRNAæ¥çš®ã¯ãå ç«ç³»ã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšéãã®ã§ã¯ãªãèããããèšç·ŽããŠããŸãããæ¥çš®åæ°ãå€ãã»ã©ãã¯ã¯ãã³ãæ»æå¯Ÿè±¡ãšããŠæããã¯ãã®ãã®ããäœãç¡èŠããããã«åŠç¿ããŠãã£ãã®ã§ãã
2023幎8æã«Nature Scientific Reportsã«æ²èŒããã远跡ç ç©¶ã¯éèŠãªç¹ãä»ãå ããŸãããæ¥çš®åã«COVIDã«ææãã人ã ã§ã¯ãåãIgG4ã®ã·ããã¯èŠãããªãã£ãã®ã§ãã圌ãã®å ç«ç³»ã¯æ»æçãªæäœãããã¡ã€ã«ãç¶æããŸãããèªç¶å ç«ã¯ãå埩æ¥çš®åç¬ãããæç¶çã§æ©èœçãªå ç«åå¿ãçã¿åºããŸãããèªç¶å ç«ã¯NPHETã«éããããã¯ã¯ãã³èšŒæå¶åºŠãæ¥çš®ã®ä»£æ¿ãšããŠèªããŸããã§ãããèªç¶å ç«ã®æ¹ãæ©èœããã®ã§ããèªç¶ææãã人ã ã¯ãæ¥çš®è ããè¯å¥œãªå ç«å¿çãæã£ãŠããŸãã
2025幎3æãJournal of Infectionã«æ²èŒãããå¥ã®ç ç©¶ããç¹ãšç¹ãçŽæ¥ã€ãªããŸãããIgG4ã®ã¯ã©ã¹ã¹ã€ããã¯SARS-CoV-2ææãªã¹ã¯ã®äžæãšé¢é£ããŠããã®ã§ããå¯å®¹åã¡ã«ããºã ã¯ä»®èª¬ã§ã¯ãããŸããã§ãããæž¬å®å¯èœã§ããã人ã ããŠã€ã«ã¹ã«å¯ŸããŠããæåæ§ã«ããŠããŸããã
ããã¯ãã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ãèªé¢ã®è·å¡51,011人ã調ã¹ããšãã«èŠåºããããšãšäžèŽããŸãããCOVID-19ã®ãªã¹ã¯ã¯ãçŽè¿ã®COVID-19眹æ£ããã®çµéæéããã³éå»ã®ã¯ã¯ãã³æ¥çš®åæ°ãå€ãã»ã©äžæããããæ¥çš®åæ°ãå€ãã»ã©ãCOVIDã«ãããå¯èœæ§ãé«ããªã£ãã®ã§ããOpen Forum Infectious DiseasesïŒãªãã¯ã¹ãã©ãŒã倧åŠåºçå±ïŒã«æ²èŒãæ»èªæžã¿ãç±³åœã§2äœã®ç é¢ããã®å ±åã§ãã
3åã4åã5åãšãåã远ãããšã«ããå®ããããšèšãããŠæ¥çš®ããã®ã§ããã°ãçºè¡šãããç§åŠã¯ããã®éãèµ·ããå¯èœæ§ã瀺åããŠããŸããå ç«ç³»ããŠã€ã«ã¹ãšéãã®ã§ã¯ãªããåŸã ã«å¯å®¹åããããèšç·ŽãããŠããŸã£ãã®ãããããŸããããããŠæš©éããç«å Žã®èª°ããããäŒããŠããŸãããäŒããããšã¯ãè·å ŽçŸ©ååãã¯ã¯ãã³èšŒæã瀟äŒçå§åã«ãã£ãŠåŒ·å¶ãããç¹°ãè¿ãã®ããŒã¹ã¿ãŒæ¿çããé广ã ã£ããããããªããšèªããããšã«ãªãããã§ãã
6:ãã€ã¢ã«ã®äžèº«
2023幎ãã²ããã¯ã¹ç ç©¶è ã®Kevin McKernanã¯ã以åŸ3倧éžã«ãããè€æ°ã®ç 究宀ã§ç¬ç«ã«ç¢ºèªãããæžå¿µãã¹ãçºèŠãããŸãããmRNAã¯ã¯ãã³ã«ã¯ã補é å·¥çšã«ç±æ¥ããDNAæ±æâæ®åãã©ã¹ããDNAâãå«ãŸããŠãããè€æ°ã®ç¬ç«è§£æã§ã欧å·å»è¬ååºïŒEMAïŒãç±³åœé£åå»è¬åå±ïŒFDAïŒãå®ããèŠå¶äžã®å®å šåºæºãæ°çŸåäžåãã¬ãã«ã§ããããšã瀺ãããã®ã§ãã
ããã¯ã¯ã¯ãã³ã®è£œé æ¹æ³ã«é¢ããéèŠãªåé¡ã§ããèšåºè©Šéšçšã®è£œåã¯é«åºŠã«ç²Ÿè£œãããããã»ã¹ã§è£œé ãããŸãããäžçäžã§æ°åååæäžããã倧éçç£åã¯ãE. coli现èãçšããç°ãªãå®äŸ¡ãªæ¹æ³ã䜿ãããŸãããããã¯ãå ãã¡ã€ã¶ãŒäž»ä»»æ¯ç©åŠè Helmut Sterzããã€ãé£éŠè°äŒãžã®èšŒèšã§è¿°ã¹ãããã»ã¹å€æŽã§ãæ¬ã·ãªãŒãºã®ããŒã3ã§åãäžããŸããã
æ±æDNAã¯åã«ååšããŠããã ãã§ãªããmRNAã现èã«å±ããè質ããç²åã«å°å ¥ãããŠããŸãããã€ãŸãDNAã¯æå¹æåãšåãééã·ã¹ãã ã«æ¢±å ããã人ã®çްèå ãžçŽæ¥å±ãçµè·¯ãåŸãŠããã®ã§ããæ€åºãããDNAé åã®äžã«ã¯ãSV40ããã¢ãŒã¿ãŒã»ãšã³ãã³ãµãŒãå«ãŸããŠããŸãããããã¯æŽå²çã«éºäŒåããªã³ã«ããããã«çç ç©¶ã§çšããããŠããéºäŒèŠçŽ ã§ãã
ãµãŠã¹ã«ãã©ã€ã倧åŠã®çã²ããã¯ã¹ææPhillip Buckhaultsã¯ãMcKernanã®æèŠãå蚌ããããšããŸããããã§ããŸããã§ãããèªèº«ã®ç 究宀ã§ç¢ºèªãã2023幎9æã«ãµãŠã¹ã«ãã©ã€ãå·äžé¢ã§çµæãå ±åããŸãããããã¡ã€ã¶ãŒã®ã¯ã¯ãã³ã«ã¯ãã©ã¹ããDNAãæ··å ¥ããŠããŸãâmRNAã ãã§ã¯ãããŸãããDNAã®æçãå ¥ã£ãŠããŸããèªåã®ç 究宀ã§ã·ãŒã±ã³ã¹ããŠç¢ºèªããŸãããã
2024幎5æã«Methods and ProtocolsïŒMDPIïŒã«æ²èŒãããæ»èªæžã¿ã®æ¹æ³è«çåæã¯ããªã補é å èªèº«ã®æ€æ»ã§ãã®æ±æãæ€åºãããªãã£ãã®ããæ€èšŒããŸãããçãã¯ããã¡ã€ã¶ãŒã®å質管çãDNAãæ€åºããéãDNAé³åé åã®1%æªæºããã¿ãŒã²ããã«ããŠããªãææ³ã䜿ã£ãŠããããã§ãããåæ°ãæž¬ã£ãŠæ®ããæ°åŠçã«å€æ¿ããŠããã®ã§ããèšãã°ã100éšå±ãã建ç©ã®ãã¡1éšå±ã ããç¹æ€ããŠã建ç©å šäœãå¥å šã ãšå®£èšãããããªãã®ã§ããã
7:ããã®ã·ã°ãã«
ããã«é¢ããã·ã°ãã«ã«ã€ããŠã¯ã2倧éžã®éå£ããŒã¿ãèšåºç çæšæ¬ãäžçã®çäŸæç®ã®ç³»çµ±çã¬ãã¥ãŒããããŠãã£ãšããããå ç«åŠçã¡ã«ããºã ããããããªãç ç©¶ãæ±ãã倿°ã®è«æãçºè¡šãããŠããŸããå®éãPubMedã§ã¯800æ¬ãè¶ ããæ»èªç ç©¶ããæ°åã³ããã¯ã¯ãã³æ¥çš®ãšå¿ççâãããŸã§å¥åº·ã ã£ã人ã ãç¹ã«è¥ãç·æ§ãå°å¹Žã«äžåè¡¡ã«èŠãããå¿èã®ççâã®é¢é£ãèšé²ããŠããŸãã
ãããŒãã£å€§åŠã®äžç ç©¶ã§ã¯ããã¹ã«ãŒã©çã®äœæ°296,015人ã2021幎6æãã2023幎12æãŸã§è¿œè·¡ããŸãããæ¥çš®è ã¯ããã§å ¥é¢ããå¯èœæ§ãçµ±èšåŠçã«ææã«é«ãã23%ã®ãªã¹ã¯äžæãèŠãããŸããã
éåœã§8,407,849人ã察象ã«ããå¥ã®ç ç©¶ã§ã¯ãæ¥çš®åŸ1幎以å ã«6çš®é¡ã®ããïŒç²ç¶è ºãããèãããå€§è žãããèºãããä¹³ãããåç«è ºããïŒã®ãªã¹ã¯ãçµ±èšåŠçã«ææã«äžæããŠããŸããã
2025å¹Žã®æ¥æ¬ã®ç ç©¶ã§ã¯ãä¹³ããçµç¹ïŒè «çïŒå ã«SARS-CoV-2ã¹ãã€ã¯ã¿ã³ãã¯è³ªããmRNAã¯ã¯ãã³ã«ç±æ¥ããå¯èœæ§ããšããŠæ€åºãããŸããã
2026幎4æãç±³åœåœç«ããç ç©¶æïŒNCIïŒã¯SEERããç£èŠããŒã¿ã2023幎åãŸã§æŽæ°ãã2021幎以éã50æ³æªæºã§çµè žçŽè žãããè³è «çãå°è žãåµå·£ãèã®ããã«ãããŠé¡èãªçºççã®å éã瀺ããŸãããããã¯ç±³åœã®å ¬åŒããçµ±èšã®æ å ±æºã§ãã
ããã¯ãEdward DowdãšRoger CunninghamïŒThe Ethical ScepticïŒã«ããç¬ç«è§£æãšãäžèŽããŠããŸãã圌ãã¯ããããã2021幎以éã®è¶ éæ»äº¡ãé害ååãããæ»äº¡çããã®ä»ã®ã·ã°ãã«ã®æ¥äžæããå ¬çããŒã¿ã»ãããçšããŠç¹å®ããŸããã
äž¡è ã¯ãçžé¢ã¯å æãæå³ããªãããšãèªãã€ã€ããããŒã¿ã®ç·æ¥ã®èª¿æ»ãæ±ããŸããã
Dowdã®ç ç©¶ã¯ãfactcheck.orgã«ãã£ãŠããã¡ã¯ããã§ãã¯ããããŸãããæ€é²è£ çœ®ïŒæ¬ã·ãªãŒãºç¬¬5éšïŒãžã®å°ããªè£è¶³ãšããŠè§ŠããŠãã䟡å€ããããŸããããã®ç¹å®ã®ãã¡ã¯ããã§ãã¯ãµã€ãã¯ãç©è°ãéžããã€ã³ã»ã³ã¯ã¯ãã³ã®è£œé å ãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã®å 瀟é·ãåµèšãããããŒãã»ãŠããã»ãžã§ã³ãœã³è²¡å£ããè³éæäŸãåããŠããŸãããã®ããã¡ã¯ããã§ãã¯ãã¯2023幎4æã«åºãããŸãããã€ã³ã»ã³ã®EUAã¯2023幎6æã«åãæ¶ãããŠããŸãã
ãããäœãæå³ããã®ã
ããªãã®å°åã§ãã©ãã«ãäœèª¿ãããããããšèšŽããŠãã人ãã¡ã¯ãåãªãæã蟌ã¿ã§ã¯ãããŸãããã¯ã¯ãã³æ¥çš®ä»¥éã以åãšåãã§ã¯ãªããªã£ãããªãã®ç¥äººã¯ãåãªãéžè©±ã§ã¯ãããŸããã圌ãã¯ã10ã«åœã»9,900äžäººä»¥äžã»å°çäžã§æãä¿¡é Œã§ããç§åŠæ©é¢ã®äžéšã«ãã£ãŠç¬ç«ã«åºç¯ã«èšé²ããããã¿ãŒã³ã®äžã®ãããŒã¿ãã€ã³ããã§ãã
ããŒã¿ã瀺ããŠããããšïŒ
èœåçã«ã¢ãã¿ãªã³ã°ããã7人ã«1人ãå»åŠçã«éç¯€ãªæå®³äºè±¡ãçµéšããŸããã300人ã«1人ã¯å¿èã®åé¡ãçºçããŸããã
補é äŒæ¥èªèº«ã®æ²»éšã§ãã¯ã¯ãã³çŸ€ã«ãããŠéç¯€ãªæå®³äºè±¡ã®éå°ã瀺ãããŸããã
mRNAã¯ã¯ãã³ã®å埩æ¥çš®ã¯ãå ç«ç³»ã«ãŠã€ã«ã¹ãšãéããã®ã§ã¯ãªãã蚱容ãããããèšç·ŽããŠããŸãããã®çµæãã¯ã¯ãã³æ¥çš®è ã¯æªæ¥çš®è ãããé »ç¹ã«æ°åã³ããã«çœ¹æ£ããŸãã
æ¥çš®åæ°ãå¢ããã»ã©ãã³ããææçãé«ããªãåŸåããããŸãã
é©åã«ã¢ãã¿ãªã³ã°ãããå代ã®è¥è ã®ã»ãŒ30%ãå¿çŸæ£ãçºçããŸããã3人ã«1人ãšããæ°åã§ãã³ããã«ããæ»äº¡ç¢ºçïŒ33,333人ã«1人ïŒãšæ¯ã¹ãŠãæ¡éãã§ãã
éç£åã«ã¯ãå®å šåºæºãæ°çŸåäžåãDNAæ±æãå«ãŸããŠããã现èå ãžçŽæ¥ééãããŸãã
å²äžæå€§èŠæš¡ã®å®å šæ§ç ç©¶ã«ãããç°è°ãå±ããå»åž«ãã¡ãæèµ·ããããããäž»èŠã·ã°ãã«ãè£ã¥ããããŸããã
è€æ°ã®ç ç©¶ã§ãã¯ã¯ãã³æ¥çš®è ã¯ããŸããŸãªçš®é¡ã®çãçºçãããªã¹ã¯ãäžæããŠããå¯èœæ§ã瀺åãããŠããŸãã
ç±³åœã®å ¬åŒããŒã¿ã¯ããŸããç¬ç«ç³»ã¢ããªã¹ãããªã¢ã«ã¿ã€ã ã§ææããŠãã¡ã¯ããã§ãã¯ã®å¯Ÿè±¡ã«ãããäºæã瀺ãå§ããŠããŸãã
ããã¯èª€æ å ±ã§ã¯ãããŸãããæ¥µå³ã®é°è¬è«ã§ããããŸãããããã¯å ¬è¡šæžã¿ã®ç§åŠã§ããäžã«æãããã¹ãŠã®ç ç©¶ã¯ãªã³ã¯ããããããããã®åŠè¡èªã§ç¢ºèªã§ããæ»èªæžã¿ã§ããªãŒãã³ã¢ã¯ã»ã¹ã§ãã€ã³ã¿ãŒãããæ¥ç¶ããããã°èª°ã§ãé²èЧã§ããŸããããŒã¿ã¯é ãããŠããŸããããã è°è«ãããŠããªãã ãã§ãããªãããšäžæè°ã«æããããããŸããã
æ²é»
ã¢ã€ã«ã©ã³ãã®ãã¹ãŠã®åžæ°ãåãã¹ããªã®ã¯ãã¯ã¯ãã³ã害ãåŒãèµ·ããããã©ããã§ã¯ãããŸãããå ¬è¡šããã蚌æ ã¯ãç·æ¥ã®èª¿æ»ã«å€ããé »åºŠã§å®³ãçããããšã瀺ããŠããŸããåãã¹ãã¯ãå ¬è¡è¡çãå®ã責åãè² ã諞æ©é¢ãããªã調æ»ããŠããªãã®ããšããããšã§ãã
ã¢ã€ã«ã©ã³ãã®å»è¬åèŠå¶åœå±ã§ããHPRAã¯ãMHRAã®ã€ãšããŒã«ãŒãã»ã¯ã¯ãã³ã¢ãã¿ãŒã«çžåœããèœåçãµãŒãã€ã©ã³ã¹ç ç©¶ãå ¬è¡šããŠããŸãããã¯ã¯ãã³æ¥çš®ãåãã10代ã®ååããªå¿èã¢ãã¿ãªã³ã°ã宿œããŠããŸãããã¢ã€ã«ã©ã³ãã®ã¯ã¯ãã³è£œé ãããã«DNAæ±æããªããã®æ€æ»ãããŠããŸããã幎霢ããªã¹ã¯ã§å±€å¥åãã害ãšå©çã®åæãå ¬è¡šããŠããŸãããGVDNã®9,900äžäººèŠæš¡ã®ç ç©¶ãIgG4ã¯ã©ã¹ã¹ã€ããã«é¢ããç ç©¶ããå ¬çãªã³ãã¥ãã±ãŒã·ã§ã³ã§äžåºŠãåŒçšããŠããŸããã
HSEã¯ã2022幎2æãã2024幎2æãŸã§25ã«æé£ç¶ã®è¶ éæ»äº¡ã«ã€ããŠèª¿æ»ããæ§åããããŸãããæ¥æ§æã®ãã³ãããã¯ãéããã¯ãã®2022幎12æã«ã27ã28%ãšããè¶ éæ»äº¡ã瀺ãããçç±ã説æããŠããŸãããè¶ éæ»äº¡ã®ã·ã°ãã«ããæ¥çš®ææãæ¥çš®åæ°ããããã¯ããããšçžé¢ããŠãããã©ãããæ€èšããŠããŸããã
ã³ãããè©äŸ¡ã¯ãå§ä»»äºé ããã¯ã¯ãã³ã®æå¹æ§ãšæå®³è»¢åž°ãæç€ºçã«é€å€ããŸãããåœå®¶ããã³ãããã¯å¯Ÿå¿ãæ€èšŒããããã«èšããå¯äžã®ä»çµã¿ã¯ããã®èŠå®èªäœã«ãã£ãŠããã³ãããã¯ã§æãé倧ã ã£ãå ¬è¡è¡çä»å ¥ãæ€èšŒã§ããªãããã«èšèšãããŠããŸããã
ãããŠã¢ã€ã«ã©ã³ãã®ã¡ãã£ã¢â2幎éã«ãããæ¯æ©ã®ææè æ°ãèªã¿äžãã1,680äžãŠãŒãã®å ¬éã§è³ãããåºåãã£ã³ããŒã³ãæŸéããNPHETã®å§åãäžåçãããšãªãåãæµããçåãåãã人ã ã«ãé ã®ããããé°è¬è«è ããšããã¬ããã«ã貌ã£ããã®åãã¡ãã£ã¢âã¯ããããã®ã©ãã«ã€ããŠãå ±ããŠããŸããã
ç ç©¶ã¯ç¶²çŸ çã§æ»èªæžã¿ã§ããæ²èŒèªã¯äžæµã®å»åŠèªã§ã蚌æ ã¯æ±ºå®çã§ããã«ãããããããè³ãã€ããããããªæ²é»ãç¶ããŠããŸãã
å®å šã§æå¹ïŒ
ãå®å šã§æå¹ãã¯ç§åŠççµè«ã§ã¯ãªããããŒã±ãã£ã³ã°çšã®ã¹ããŒã¬ã³ã§ããã補é äŒç€Ÿèªèº«ã®æ²»éšããŒã¿ã¯ãéç¯€ãªæå®³äºè±¡ã®è¶ éã瀺ããŠããŸãããèŠå¶åœå±èªèº«ã®èœåçã¢ãã¿ãªã³ã°ã§ã¯ã7人ã«1人ãå»åŠçã«æ·±å»ãªåå¿ãå ±åããŠããŸããããããŸã§ã§æå€§ã®å®å šæ§ç ç©¶ã¯ãç°è«ãå±ããå»åž«ãã¡ãææããŠç Žå£ããããããããäž»èŠã·ã°ãã«ãè£ã¥ããŸãããå ç«ã¡ã«ããºã ã®ããŒã¿ã¯ãå埩æäžãé广ã«ãªãåŸãããšã瀺ããŠããŸãã3補åã®ãã¡2ã€ã¯æ€åãããŸããã
å»çå°éè·ã®ã¯ã¯ãã³ãžã®ä¿¡é Œãæºããã2024/25幎ã®å»çåŸäºè ã«ãããæ°åã³ããã¯ã¯ãã³æ¥çš®çã¯12%æªæºã«äœäžããŸãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã®æ¥çš®çã2022幎ã®71%ãã2025幎ã«ã¯45%ã«äžãããŸããã
ãããŠã¢ã€ã«ã©ã³ãåœå®¶â瀟äŒçå§åãè·å Žã§ã®å§åãç«æ³ã«ããæé€ãå»çäžã®ç°è«ã®æå§ãéããŠãäºå®äžã¯ã¯ãã³æ¥çš®ã匷å¶ãããã®åœå®¶âã¯ãäžçäžã§å€§èŠæš¡ã«èšé²ãããŠãããããã害ã«ã€ããŠãåäžã®ç ç©¶ããã¬ãã¥ãŒãã調æ»ãè¡ã£ãŠããŸããã
ç§åŠãä¿¡ããïŒ
ãç§åŠãä¿¡ããããšãããã¬ãŒãºã¯ãå»ç§åŠãšããåéãšãäžè¬çãªæš©åšã«èšãç¥ããªãæå®³ãäžããŸãããæ£ããããšãããŠããã€ããã ã£ãæ®éã®äººã ããåã³æš©åè ãä¿¡é Œã§ãããšã¯èãã«ããã®ã§ãã
ã¢ã€ã«ã©ã³ãæ¿åºã¯åœå®¶å ¬è¡è¡çç·æ¥äºæ ããŒã ïŒNPHETïŒã«åœã®ç·æ¥å¯Ÿå¿ãä»»ããã»ãšãã©éã®èŠåŸã«è¿ã圢ã§éé ãæ¯ããããšãèš±ããŸãããã®ã¡ã«ãç«åŠçå°éæ§ã®æ¬ åŠãèªããŸãããçµéšè±å¯ãªå»åž«ãã¡ãæžå¿µã瀺ãããšãã圌ãã¯å³åº§ã«æã¡èœãšãããæ²ææç¶ããéãããã¡ãã£ã¢ã«ãã£ãŠä¿¡çšãæãªãããŸãããé«éœ¢è ã¯ä»è·æœèšã§èŠæšãŠãããå©çšå¯èœãªç åºã¯ç©ºãããŸãŸã§ããã4幎以äžåããåºåã£ãŠããèŸèŸ£ãªå°éå®¶è«æã§ãããä¿å¥æ¿çã«åœ±é¿ãäžããããã¥ãŒã¹ã®èŠåºãã«ããªã£ãŠããŸãããæ°åã³ããã¯ã¯ãã³ã¯é倧ãªå®³ãåŒãèµ·ãããŸãããŸããæ¥çš®è ã®æ¹ãã³ããã«ãããããããªããŸããããªãã«ã¯ãå®å šã§æå¹ãã ãšèšãããŠããŸããã
å°ãªããšããã¢ã€ã«ã©ã³ãã®äººã ãåœç¶åããã¹ããªã®ã¯èª å®ãã§ãã人ã ã¯å ¬è¡è¡çæ©é¢ãä¿¡é Œããæ¿åºãä¿¡é Œããã¡ãã£ã¢ãä¿¡é ŒããŸããããã®æ å ±ã«åãåããªãããšã§ããã®ä¿¡é Œã¯ä»ãèžã¿ã«ããããŠããŸãã
ãã®ä»£åã¯ã倱ãããåœãçèšãå·ã€ããå ç«ç³»ãçºéã®äœå¹Žãã倱ã£ãåã©ããã¡ãå¿èã®åé¡ãæ±ããããšã«ãªã£ã10代ãç¡çºã«ç¬ãã§æ»ãªãããããããªãé«éœ¢è ããæ£ãã質åãããããããã«ãã£ãªã¢ãç Žå£ãããå»åž«ãã¡ããããŠäžäžä»£ãèŠããŠãå埩ã§ãããåãããªãä¿¡é Œã®æ¬ åŠãšãªã£ãŠè¡šããŠããŸãã
ç§åŠã¯æ±ºããŠã確å®ãããŠããŸããã§ãããçããããŠããªãåããããŸãã«ãå€ãã®ã§ããããããç§åŠãä¿¡ããããšäž»åŒµããŠãã人ã ã¯ä»ãçŸå®ã®ããŒã¿ãšåãåãããšãæã¿ããªãã£ãããšã«ããããšããŠãç§åŠããã ãããã®äžã«æã蟌ãã§ããŸãã
仿¬åœã«éèŠãªåãã¯ãã äžã€ã§ãã
説æè²¬ä»»ãæ¬ åŠããŠããç¶æ³ã§ãåžæ°ã¯ã©ããã£ãŠåœå±ãäºåºŠãšåãããšãèµ·ãããªããšä¿¡ããããã®ã§ããããã
ããã¯ãç§åŠãä¿¡ããâã¢ã€ã«ã©ã³ãã®ã³ããç·æ±ºç®ãæçµåã§ããå šã·ãªãŒãºã¯ããŒã«ã»ãããã³ã®Substackã§ã芧ããã ããŸãã
